Kun Cheng

Assistant Professor

Division of Pharmaceutical Sciences
Ph.: 816-235-2425
Fax: 816-235-5779
E-mail: chengkun@umkc.edu

Address:

UMKC School of Pharmacy
2464 Charlotte St.
NHSB 5250
Kansas City, MO 64108

» Cheng Lab Website

» Research Interests

» Recent Publications

» Recent Book Chapters

» Recent Journal Theme Issue Editor

» Recent Grants

» Teaching

Research Interests

• Development of nucleic acid therapy for cancer, liver disease, and islet transplantation
• Development of targeted delivery system for therapeutic macromolecules
• Synthesis of novel polymers for nucleic acid drug delivery
• Identification of molecular ligand for specific cells
• Designing of anti-tumor prodrug for improving target-ability and efficiency
• Development of biocompatible hydrogels for stem cell research

Recent publications

1. Ravi S. Shukla, Bin Qin, Kun Cheng. (2011) PCBP2 siRNA reverses the alcohol-induced pro-fibrogenic effect in hepatic stellate cells. Pharmaceutical Research 2011 Jun 4. [Epub ahead of print]
2. Bin Qin, Wanyi Tai, Ravi S. Shukla, Kun Cheng. (2011) Identification of a prostate cancer specific peptide using phage display. Pharmaceutical Research 2011 May 25 [Epub ahead of print]
3. Wanyi Tai, Ravi S. Shukla, Bin Qin, Benyi Li, Kun Cheng. (2011) Development of a peptide-drug conjugate for prostate cancer therapy. Molecular Pharmaceutics 8(3):901-12 [Epub 2011 May 3]
4. Rubi Mahato, Wanyi Tai, Kun Cheng. (2011) Prodrugs for improving tumor targetability and efficiency. Advanced Drug Delivery Review 2011 Feb 16. [Epub ahead of print]
5. Rubi Mahato, Bin Qin, Kun Cheng. (2010) Blocking IKK-α Expression Inhibits Prostate Cancer Invasiveness. Pharmaceutical Research [Dec 30, Epub ahead of print]
6. Bin Qin, Kun Cheng. (2010) Silencing of the IKKɛ gene by siRNA inhibits growth and invasiveness of breast cancer cells. Breast Cancer Research 12(5):R74. [Epub ahead of print]
7. Wanyi Tai, Rubi Mahato, Kun Cheng. (2010) The role of HER2 in cancer therapy and targeted drug delivery. Journal of Controlled Release 146(3):264-75
8. Wanyi Tai, Bin Qin, Kun Cheng. (2010) The combinational effect of HER-2 and VEGF siRNAs on breast cancer cells. Molecular Pharmaceutics 7(2): 543-556
9. Kun Cheng, Ram I. Mahato (2009) siRNA delivery and targeting. Molecular Pharmaceutics. 6(3):649-650, Editorial
10. Kun Cheng, NingNing Yang, Ram I. Mahato (2009) TGF-β1 Gene Silencing for Treating Liver Fibrosis. Molecular Pharmaceutics 6(3):772-779
11. Lin Zhu, Zhaoyang Ye, Kun Cheng, Duane D. Miller, Ram I. Mahato (2008), Site-specific Delivery of Oligonucleotides to Hepatocytes after Systemic Administration. Bioconjugate Chemistry, 19:290-298
12. Kun Cheng, Ram I. Mahato (2007) Gene Modulation for Treating Liver Fibrosis (review) Critical Reviews in Therapeutic Drug Carrier Systems, 24:93-146
13. Xiangxu Jia, Kun Cheng, Ram I. Mahato (2007) Co-expression of Vascular Endothelial Growth Factor and Interleukin-1 Receptor Antagonist for Improved Human Islet Survival and Function. Molecular Pharmaceutics, 4:199-207

Recent book chapters:

1. Bin Qin, Ravi S. Shukla, Kun Cheng (2011) “Delivery of nucleic acids for ocular gene modulation” in Mitra AK edits “Advances in Ocular Drug Delivery”, Research Singpost/Transworld Research Network, (in press)
2. Kun Cheng, Bin Qin. (2009) RNA Interference for Cancer Therapy in Lu Y, Mahato RI. edits “Pharmaceutical Perspectives of Cancer Therapeutics”, AAPS-Springer publishing program
3. Kun Cheng, Ram I. Mahato. (2006) Biopharmaceutical Challenges in Pulmonary Delivery of Proteins and Peptides in Meibohm B. edits “Pharmacokinetics and Pharmacokinetics of Biotech Drugs”, Wiley-VCH, Weinheim, Germany

Recent Journal Theme Issue Editor:

1. Cheng K and Mahato RI (Eds) Special Issue entitled “siRNA Delivery” (2009) Molecular. Pharmaceutics. 6(3):649-1040

Recent grants:

1. Targeted delivery of IKKα siRNA to prostate cancer cells (1R21CA143683-01); National Cancer Institute (NCI), NIH; 01/01/2010~12/31/2011; Role: PI
2. Treating Alcoholic Liver Fibrosis by Reversal of Type I Collagen (1R21AA017960-01A1); National Institute of Alcohol Abuse and Alcoholism (NIAAA), NIH; 09/10/2009~08/31/2011; Role: PI
3. Department of Defense (DOD), Breast Cancer Research Program (BCRP), Concept Award, ($109,086), 09/30/2008 ~ 09/30/2009, Role: PI

Teaching:

1. PHAR 5634 Protein and Nucleic Acid Drug Delivery (Graduate course, 3 credit hours)
Role: Coordinator
2. PHAR 5531 Physical Pharmacy Equilibria (Graduate course, 3 credit hours)
Role: Instructor
3. PHAR 5632 Novel Drug Delivery Systems (Graduate course, 3 credit hours)
Role: Instructor
4. PHAR 5631 Pharmaceutical formulation I (Graduate course, 3 credit hours)
Role: Instructor
5. PHAR 7202 Pharmaceutics I (PharmD course, 4 credit hours)
Role: Instructor
6. PHAR 7203 Pharmaceutics II (PharmD course, 4 credit hours)
Role: Instructor